Compare Coupang Inc (CPNG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Mesoblast Limited — how do they compare? Coupang Inc trades at $15.82 (market cap $27.70B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Coupang Inc is far larger — about 15.8× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 27,703,608). Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Mesoblast Limited for 15 Days on average.
| CPNG | MESO | |
|---|---|---|
Market Cap | $27.70B | $1.75B |
Volume | 27,703,608 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.13 | $20.96 |
52-Week Low | $13.75 | $13.19 |
Typical Hold Time | 55 Days | 15 Days |
Enterprise Value | $27.22B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $15.41, up 4.05% today, with a bullish technical signal and strong analyst support. Revenue grew to $34.53B in 2025, though recent quarterly EPS misses and a negative net income margin of -2.16% highlight profitability challenges. The stock is supported by positive cash flow from operations of $1.77B and a dominant e-commerce position in South Korea, but faces competitive pressure and a projected net loss in 2026.
The outlook balances high growth potential against near-term earnings volatility. Investment appeal lies in market dominance and analyst consensus price target of $25.25, implying significant upside, but risks include intense competition, regulatory scrutiny from U.S.-South Korea trade tensions (CNBC, 2026-08-31), and execution hurdles in expanding logistics networks.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
